Anzeige
Mehr »
Login
Sonntag, 18.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Überraschende News bei BIOTECH-PERLE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QFAQ ISIN: US81181C1045 Ticker-Symbol: SGT 
Tradegate
15.04.21
16:56 Uhr
125,98 Euro
+5,56
+4,62 %
1-Jahres-Chart
SEAGEN INC Chart 1 Jahr
5-Tage-Chart
SEAGEN INC 5-Tage-Chart
RealtimeGeldBriefZeit
120,16122,6217.04.
120,04122,6416.04.

Aktuelle News zur SEAGEN Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SEAGEN Aktie jetzt für 0€ handeln
MiOn a roll, Gilead snags 2nd Trodelvy nod-in bladder cancer-but Seagen and Astellas have set the bar high26
MoJazz Pharmaceuticals pushes to expand label on Xywav; FDA eyes October for decision on Seagen's latest ADC6
MoSeagen: The New Oncology Hope6
09.04.FDA accepts Genmab, Seagen's tisotumab vedotin BLA application for review3
09.04.Genmab A/S: Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer398FDA action date is Oct 10, 2021 BLA submission supported by positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020 Genmab...
► Artikel lesen
09.04.Seagen Inc.: Seagen and Genmab Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer308- FDA Action Date is October 10, 2021 - - BLA Submission Supported by Positive Pivotal innovaTV 204 Trial Results Presented at the European Society of Medical Oncology Virtual Congress 2020 -...
► Artikel lesen
09.04.Genmab A/S: Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients ...3
29.03.Seagen's (SGEN) MAA for Enfortumab Vedotin Gets EMA Acceptance7
26.03.The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs11
26.03.EMA accepts Astellas/Seagen's enfortumab vedotin for review5
26.03.EMA accepts Astellas, Seagen's enfortumab vedotin application in urothelial cancer3
26.03.Seagen: EMA Accepts MAA Of Enfortumab Vedotin For Urothelial Cancer Treatment345WASHINGTON (dpa-AFX) - Astellas Pharma Inc. and Seagen Inc. (SGEN) said that the European Medicines Agency or EMA accepted a marketing authorization application for enfortumab vedotin. Enfortumab...
► Artikel lesen
26.03.Seagen Inc.: European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin286- Enfortumab vedotin to be reviewed under accelerated assessment for the treatment of locally advanced or metastatic urothelial cancer - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji...
► Artikel lesen
25.03.Pieris Pharma Wavers After $13M Seagen Equity Investment5
25.03.Seagen invests $13M in Pieris, inks deal for PRS-343 + Tuksya in gastric cancer5
25.03.Pieris Pharmaceuticals, Inc.: Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen333Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target...
► Artikel lesen
17.03.SEAGEN - Als Anleger sollte man jetzt ganz genau hinschauen!25
05.03.Seagen warns investors against TRC Capital's latest 'mini-tender offer'; BeiGene goes after a new indication for top PD-1 player17
05.03.Seagen recommends rejection of 'mini-tender' offer from TRC capital4
23.02.UK approval for Seagen's oral HER2 inhibitor Tukysa6
Seite:  Weiter >>
95 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,2,9